Alder Biopharmaceuticals, Inc. clinical trials
Acquired by H. Lundbeck A/S, Oct 22, 2019 · source ↗
The registry lists 6 studies whose lead sponsor is Alder Biopharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 9, 2020.
Before and after it joined H. Lundbeck A/S
- First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- 6
- First submitted after Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 6
Registry sponsor names on this page
- Alder Biopharmaceuticals, Inc.6 studies
Something wrong with this grouping? Tell us on the H. Lundbeck A/S page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All H. Lundbeck A/S studies →
- Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic MigraineCompletedNCT02974153Phase 3
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- A Multicenter Assessment of ALD403 in Frequent Episodic MigraineCompletedNCT02559895Phase 3
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- An Open Label Trial of ALD403 (Eptinezumab) in Chronic MigraineCompletedNCT02985398Phase 3
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- A Multicenter Assessment of ALD403 in Chronic MigraineCompletedNCT02275117Phase 2
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- Safety, Efficacy and Pharmacokinetics of ALD403CompletedNCT01772524Phase 1
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S
- Safety Tolerability and Pharmacokinetics of ALD403CompletedNCT01579383Phase 1
Sponsor listed in the registry: Alder Biopharmaceuticals, Inc. · First submitted before Alder Biopharmaceuticals, Inc. became part of H. Lundbeck A/S